Shire

Ex-Shire drug improves outcomes in phase 2 autoimmune trial

Nine years after Shire paid $75 million for FT011, Certa linked the candidate to improvements in the symptoms of a rare autoimmune disease in phase 2.

Nick Paul Taylor Feb 6, 2023 6:15am

FDA shores up executive team with 2 hires—Chutes & Ladders

Jul 1, 2022 9:30am

Takeda scraps dream of getting rare disease drug to market

May 11, 2022 8:30am

Ladders climb many up clouds reach the sky

Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders

May 6, 2022 9:30am

Takeda shunts jewel of Shire takeover to new spinoff Oak Hill

Feb 1, 2022 8:30am

Sage's COO and bluebird's CMO to hit the exit—Chutes & Ladders

Mar 19, 2021 9:30am